$STIM
Neuronetics Inc

2020 Q4 Form 10-K Financial Statement

#000156459021010320 Filed on March 02, 2021

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2020 Q2
Revenue $15.58M $12.45M $9.741M
YoY Change -10.24% -22.2% -41.22%
Cost Of Revenue $3.763M $2.657M $2.323M
YoY Change -10.81% -36.62% -44.31%
Gross Profit $11.82M $9.791M $7.418M
YoY Change -10.06% -17.08% -40.18%
Gross Profit Margin 75.85% 78.66% 76.15%
Selling, General & Admin $12.36M $10.26M $12.16M
YoY Change -21.89% -29.93% -22.95%
% of Gross Profit 104.64% 104.82% 163.94%
Research & Development $2.112M $1.952M $2.116M
YoY Change -50.28% -44.05% -34.37%
% of Gross Profit 17.87% 19.94% 28.53%
Depreciation & Amortization $200.0K $210.0K $230.0K
YoY Change -33.33% -32.26% -11.54%
% of Gross Profit 1.69% 2.14% 3.1%
Operating Expenses $14.48M $12.22M $14.28M
YoY Change -27.89% -32.65% -24.89%
Operating Profit -$2.660M -$2.424M -$6.859M
YoY Change -61.67% -61.69% 3.81%
Interest Expense $1.011M $1.002M $986.0K
YoY Change 11.71% 7.74% 5.91%
% of Operating Profit
Other Income/Expense, Net $14.00K $8.000K $80.00K
YoY Change -95.17% -97.95% -81.98%
Pretax Income -$3.660M -$3.420M -$7.770M
YoY Change -51.52% -50.22% 9.59%
Income Tax
% Of Pretax Income
Net Earnings -$3.657M -$3.418M -$7.765M
YoY Change -51.59% -50.23% 9.46%
Net Earnings / Revenue -23.47% -27.46% -79.71%
Basic Earnings Per Share -$0.18 -$0.41
Diluted Earnings Per Share -$192.4K -$0.18 -$0.41
COMMON SHARES
Basic Shares Outstanding 18.89M 18.75M
Diluted Shares Outstanding 18.89M 18.75M

Balance Sheet

Concept 2020 Q4 2020 Q3 2020 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $49.00M $50.70M $54.00M
YoY Change -35.27% -38.47% -39.73%
Cash & Equivalents $48.96M $50.70M $54.00M
Short-Term Investments
Other Short-Term Assets $3.300M $3.500M $1.900M
YoY Change 32.0% 45.83% 46.15%
Inventory $3.720M $3.800M $3.332M
Prepaid Expenses $1.096M $851.0K
Receivables $7.166M $5.564M $6.636M
Other Receivables $1.900M $1.600M $1.300M
Total Short-Term Assets $65.01M $65.20M $67.21M
YoY Change -26.5% -32.02% -33.65%
LONG-TERM ASSETS
Property, Plant & Equipment $730.0K $787.0K $828.0K
YoY Change -34.06% -21.85% -25.07%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.866M $6.600M $1.922M
YoY Change 42.99% 509.42% 49.69%
Total Long-Term Assets $13.65M $13.10M $12.78M
YoY Change 16.45% 36.81% 57.24%
TOTAL ASSETS
Total Short-Term Assets $65.01M $65.20M $67.21M
Total Long-Term Assets $13.65M $13.10M $12.78M
Total Assets $78.66M $78.30M $79.99M
YoY Change -21.47% -25.77% -26.9%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.749M $2.400M $2.324M
YoY Change -18.94% -41.59% -36.49%
Accrued Expenses $7.319M $6.171M $5.661M
YoY Change -18.96% -18.93% -12.58%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due $34.54M $34.37M
YoY Change 360.56% 816.61%
Total Short-Term Liabilities $13.68M $45.80M $45.35M
YoY Change -50.59% 108.16% 173.07%
LONG-TERM LIABILITIES
Long-Term Debt $34.62M $0.00 $0.00
YoY Change 73.99% -100.0% -100.0%
Other Long-Term Liabilities $4.900M $5.100M $5.200M
YoY Change 4.26% -10.53% -13.33%
Total Long-Term Liabilities $34.62M $5.100M $5.200M
YoY Change 73.99% -78.25% -80.75%
TOTAL LIABILITIES
Total Short-Term Liabilities $13.68M $45.80M $45.35M
Total Long-Term Liabilities $34.62M $5.100M $5.200M
Total Liabilities $53.16M $50.90M $50.55M
YoY Change 1.62% -0.49% 1.91%
SHAREHOLDERS EQUITY
Retained Earnings -$277.5M -$273.9M -$270.5M
YoY Change 10.98% 12.93% 14.78%
Common Stock $303.0M $299.9M
YoY Change 1.71% 1.5%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $25.49M $27.48M $29.44M
YoY Change
Total Liabilities & Shareholders Equity $78.66M $78.30M $79.99M
YoY Change -21.47% -25.77% -26.9%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2020 Q2
OPERATING ACTIVITIES
Net Income -$3.657M -$3.418M -$7.765M
YoY Change -51.59% -50.23% 9.46%
Depreciation, Depletion And Amortization $200.0K $210.0K $230.0K
YoY Change -33.33% -32.26% -11.54%
Cash From Operating Activities -$1.700M -$3.560M -$9.480M
YoY Change -73.44% -53.52% 38.39%
INVESTING ACTIVITIES
Capital Expenditures -$110.0K -$140.0K -$210.0K
YoY Change -69.44% 180.0% 61.54%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$110.0K -$140.0K -$210.0K
YoY Change -69.44% 180.0% 61.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 60.00K 410.0K 40.00K
YoY Change -40.0% -6.82% -91.49%
NET CHANGE
Cash From Operating Activities -1.700M -3.560M -9.480M
Cash From Investing Activities -110.0K -140.0K -210.0K
Cash From Financing Activities 60.00K 410.0K 40.00K
Net Change In Cash -1.750M -3.290M -9.650M
YoY Change -73.72% -54.75% 48.23%
FREE CASH FLOW
Cash From Operating Activities -$1.700M -$3.560M -$9.480M
Capital Expenditures -$110.0K -$140.0K -$210.0K
Free Cash Flow -$1.590M -$3.420M -$9.270M
YoY Change -73.68% -55.06% 37.95%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 stim Distribution Agreement Period
DistributionAgreementPeriod
P7Y6M
CY2017 stim Distribution Agreement Period
DistributionAgreementPeriod
P7Y6M
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1
RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1
P1Y
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
75708000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6569000
CY2019Q4 us-gaap Inventory Net
InventoryNet
2775000
CY2020Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
1887000
CY2019Q4 us-gaap Net Investment In Lease Current
NetInvestmentInLeaseCurrent
880000
CY2020Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1096000
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
689000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2186000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1830000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
65012000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-29044000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
4625000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
88451000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
730000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1107000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3418000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3796000
CY2020Q4 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
2331000
CY2019Q4 us-gaap Net Investment In Lease Noncurrent
NetInvestmentInLeaseNoncurrent
1730000
CY2020Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
5300000
CY2019Q4 us-gaap Prepaid Expense Noncurrent
PrepaidExpenseNoncurrent
3779000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1866000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1305000
CY2020Q4 us-gaap Assets
Assets
78657000
CY2019Q4 us-gaap Assets
Assets
100168000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3749000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7319000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9031000
CY2020Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2020000
CY2019Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
2228000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
594000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
559000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
11250000
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13682000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
27693000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
34620000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
19898000
CY2020Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1741000
CY2019Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
2106000
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3121000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2619000
CY2020Q4 us-gaap Liabilities
Liabilities
53164000
CY2019Q4 us-gaap Liabilities
Liabilities
52316000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19114000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19114000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18645000
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
18645000
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
191000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
186000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
302842000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
297753000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-277540000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-250087000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-26930000
CY2018 us-gaap Operating Income Loss
OperatingIncomeLoss
-19834000
CY2018 us-gaap Interest Expense
InterestExpense
3688000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
25493000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
47852000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
78657000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
100168000
CY2020 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
49244000
CY2019 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
62656000
CY2018 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
52776000
CY2019 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
15389000
CY2018 us-gaap Cost Of Goods And Services Sold
CostOfGoodsAndServicesSold
12447000
CY2018 us-gaap Gross Profit
GrossProfit
40329000
CY2020 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9201000
CY2020 us-gaap Operating Expenses
OperatingExpenses
59999000
CY2019 us-gaap Operating Expenses
OperatingExpenses
74197000
CY2020 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-924000
CY2018 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-575000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
-192652000
CY2018 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
187136000
CY2018 stim Adjustments To Additional Paid In Capital Conversion Of Convertible Preferred Stock Warrants Into Common Stock Warrants
AdjustmentsToAdditionalPaidInCapitalConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrants
1874000
CY2018 stim Issuance Costs On Issuance Of Common Stock
IssuanceCostsOnIssuanceOfCommonStock
3463000
CY2018 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
96535000
CY2018 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
503000
CY2018 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1743000
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-24097000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
71042000
CY2020 us-gaap Profit Loss
ProfitLoss
-27453000
CY2019 us-gaap Profit Loss
ProfitLoss
-29044000
CY2018 us-gaap Profit Loss
ProfitLoss
-24097000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
941000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1065000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
4404000
CY2018 us-gaap Amortization Of Financing Costs And Discounts
AmortizationOfFinancingCostsAndDiscounts
839000
CY2018 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
1396000
CY2019 stim Cost Of Rental Units Purchased By Customers
CostOfRentalUnitsPurchasedByCustomers
223000
CY2018 stim Cost Of Rental Units Purchased By Customers
CostOfRentalUnitsPurchasedByCustomers
229000
CY2020 stim Non Cash Gains Losses On Extinguishment Of Debt
NonCashGainsLossesOnExtinguishmentOfDebt
-622000
CY2020 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
597000
CY2019 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
950000
CY2018 us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1353000
CY2020 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
945000
CY2019 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
306000
CY2018 us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
435000
CY2020 stim Increase Decrease In Net Investment In Sales Type Leases
IncreaseDecreaseInNetInvestmentInSalesTypeLeases
1609000
CY2019 stim Increase Decrease In Net Investment In Sales Type Leases
IncreaseDecreaseInNetInvestmentInSalesTypeLeases
2610000
CY2020 stim Increase Decrease In Leasehold Reimbursement
IncreaseDecreaseInLeaseholdReimbursement
-836000
CY2020 stim Increase Decrease In Prepaid Commission Expense
IncreaseDecreaseInPrepaidCommissionExpense
1928000
CY2019 stim Increase Decrease In Prepaid Commission Expense
IncreaseDecreaseInPrepaidCommissionExpense
4468000
CY2020 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
641000
CY2019 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
565000
CY2018 us-gaap Increase Decrease In Prepaid Expenses Other
IncreaseDecreaseInPrepaidExpensesOther
237000
CY2020 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1085000
CY2019 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
299000
CY2018 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
606000
CY2020 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-1733000
CY2019 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1549000
CY2020 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-573000
CY2018 us-gaap Increase Decrease In Deferred Leasing Fees
IncreaseDecreaseInDeferredLeasingFees
63000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30482000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20591000
CY2020 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
730000
CY2019 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
813000
CY2018 us-gaap Payments To Acquire Productive Assets
PaymentsToAcquireProductiveAssets
1011000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-730000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-813000
CY2018 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1011000
CY2020 us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
41360000
CY2020 us-gaap Repayments Of Long Term Debt
RepaymentsOfLongTermDebt
38860000
CY2020 us-gaap Payments Of Debt Issuance Costs
PaymentsOfDebtIssuanceCosts
821000
CY2020 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
690000
CY2019 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
2420000
CY2018 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
503000
CY2018 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
99998000
CY2018 us-gaap Conversion Of Stock Amount Converted1
ConversionOfStockAmountConverted1
187136000
CY2020 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
208000
CY2019 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
377000
CY2018 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
263000
CY2018 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
3463000
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2369000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
2420000
CY2018 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
97038000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-26751000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
-28875000
CY2018 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect
75436000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75708000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104583000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
29147000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
48957000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
75708000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
104583000
CY2020 us-gaap Interest Paid Net
InterestPaidNet
3892000
CY2019 us-gaap Interest Paid Net
InterestPaidNet
2949000
CY2018 us-gaap Interest Paid Net
InterestPaidNet
2786000
CY2019 stim Transfer Of Inventory To Property And Equipment
TransferOfInventoryToPropertyAndEquipment
37000
CY2018 stim Transfer Of Inventory To Property And Equipment
TransferOfInventoryToPropertyAndEquipment
365000
CY2018 stim Conversion Of Convertible Preferred Stock Warrants Into Common Stock Warrant
ConversionOfConvertiblePreferredStockWarrantsIntoCommonStockWarrant
1874000
CY2020 us-gaap Nature Of Operations
NatureOfOperations
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:12pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>DESCRIPTION OF BUSINESS </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Neuronetics, Inc., or the Company, is a commercial stage medical technology company focused on designing, developing and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. The Company’s first commercial product, the NeuroStar Advanced Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The system was cleared in 2008 by the United States Food and Drug Administration, or the FDA, to treat adult patients with major depressive disorder, or MDD, who have failed to achieve satisfactory improvement from prior antidepressant medication in the current episode. The Company intends to continue to pursue development of its NeuroStar Advanced Therapy System for additional indications.  </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COVID-19</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is monitoring the impact of the COVID-19 pandemic on all aspects of its business and geographies, including how it will impact the Company’s customers, supply chain, employees and other business partners. While the Company experienced significant disruptions in March 2020 through the end of December 2020, from the COVID-19 pandemic, it is unable to predict the full impact that the COVID-19 pandemic may have on its financial condition, results of operations and cash flows due to numerous uncertainties. These uncertainties include the scope, severity and duration of the pandemic, the actions taken to contain the pandemic or mitigate its impact and the direct and indirect economic effects of the pandemic and containment measures, among others. The outbreak of COVID-19 in many countries, including the United States, has significantly adversely impacted global economic activity and has contributed to significant volatility and negative pressure in financial markets.</p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company applied for and received a $6.4 million loan in April 2020 under the Paycheck Protection Program (the “PPP”) established by the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) on March 27, 2020. Due to questions concerning the eligibility of public companies similarly situated to the Company, on May 7, 2020, the Company repaid the loan in full, including interest accrued to date.</p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity</p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2020, the Company had cash and cash equivalents of $49.0 million and an accumulated deficit of $277.5 million. The Company incurred negative cash flows from operating activities of $28.4 million, $30.5 million and $20.6 million for the years ended December 31, 2020, 2019, and 2018, respectively. The Company has incurred operating losses since its inception, and management anticipates that its operating losses will continue in the near term as the Company seeks to expand its sales and marketing initiatives to support its growth into existing and new markets and invest in additional research and development activities. The Company’s primary sources of capital to date have been from its IPO, private placements of its convertible preferred securities, borrowings under its credit facilities and revenues from sales of its products. As of December 31, 2020, the Company had $35.0 million of borrowings outstanding under its credit facility, which matures in <span style="-sec-ix-hidden:F_000361">February 2025</span>. Management believes that the Company’s cash and cash equivalents as of December 31, 2020, in addition to the $80.6 million in net proceeds raised from our public offering and sale of our common stock (the “Offering”) completed in February 2021, and anticipated revenues from sales of our products are sufficient to fund the Company’s operations for at least the next 12 months from the issuance of these financial statements.<span style="font-size:12pt;"> </span></p> <p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"> </p>
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
49000000.0
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-277500000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-28400000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-30500000
CY2018 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-20600000
CY2020 us-gaap Basis Of Accounting
BasisOfAccounting
<div style="align:left;"> <table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:3.4%;white-space:nowrap" valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><span style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.</span></p></td> <td valign="top"> <p style="margin-bottom:0pt;margin-top:18pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><span style="font-weight:normal;"/>BASIS OF PRESENTATION </p></td></tr></table></div> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying financial statements have been prepared in accordance with United States generally accepted accounting principles, or GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification, or ASC, and Accounting Standards Updates, or ASUs, promulgated by the Financial Accounting Standards Board, or FASB. </p> <p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with GAAP and the rules and regulations of the United States Securities and Exchange Commission, or SEC, requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. </p>
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in accordance with GAAP and the rules and regulations of the United States Securities and Exchange Commission, or SEC, requires the use of estimates and assumptions, based on judgments considered reasonable, which affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. The Company bases its estimates and assumptions on historical experience, known trends and events and various other factors that management believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. Although management believes its estimates and assumptions are reasonable when made, they are based upon information available at the time they are made. Management evaluates the estimates and assumptions on an ongoing basis and, if necessary, makes adjustments. Due to the risks and uncertainties involved in the Company’s business and evolving market conditions and given the subjective element of the estimates and assumptions made, actual results may differ from estimated results. </p>
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2207000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
730000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1107000
CY2020 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
CY2019 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1100000
CY2018 us-gaap Depreciation And Amortization
DepreciationAndAmortization
900000
CY2020 us-gaap Revenue Performance Obligation Description Of Warranty
RevenuePerformanceObligationDescriptionOfWarranty
The Company provides a two-year warranty on all new System sales which were determined to be assurance-type warranties and thus not considered a separate performance obligation. The Company accrues the cost of providing these warranties
CY2020Q4 us-gaap Contract With Customer Right To Recover Product
ContractWithCustomerRightToRecoverProduct
0
CY2020 stim Distribution Agreement Renewal Period
DistributionAgreementRenewalPeriod
P2Y
CY2020 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Credit Risk </p> <p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s cash is held on deposit in demand accounts at a large financial institution in amounts in excess of the Federal Deposit Insurance Corporation, or FDIC, insurance coverage limit of $250,000 per depositor, per FDIC-insured bank, per ownership category. Management has reviewed the financial statements of this institution and believes it has sufficient assets and liquidity to conduct its operations in the ordinary course of business with little or no credit risk to the Company. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk principally consist of cash equivalents and accounts receivable. The Company limits its credit risk associated with cash equivalents by placing investments in highly-rated money market funds. The Company limits its credit risk with respect to accounts receivable by performing credit evaluations when deemed necessary, but it does not require collateral to secure amounts owed by its customers. </p>
CY2020Q4 us-gaap Time Deposits At Or Above Fdic Insurance Limit
TimeDepositsAtOrAboveFDICInsuranceLimit
250000
CY2020 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2019 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2018 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.15
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.16
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.16
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
0.04
CY2020Q4 us-gaap Revenue Remaining Performance Obligation Percentage
RevenueRemainingPerformanceObligationPercentage
1
CY2020 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2000000.0
CY2019 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
2200000
CY2020 stim Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
1
CY2019 stim Number Of Customer Accounted For More Than Ten Percentage Of Revenues
NumberOfCustomerAccountedForMoreThanTenPercentageOfRevenues
0
CY2020Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
8178000
CY2019Q4 us-gaap Accounts Receivable Gross Current
AccountsReceivableGrossCurrent
7117000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1012000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
548000
CY2020Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
7166000
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
6569000
CY2017Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
417000
CY2018 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
153000
CY2018 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
70000
CY2018Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
500000
CY2019 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
353000
CY2019 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
305000
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
548000
CY2020 us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
897000
CY2020 us-gaap Allowance For Doubtful Accounts Receivable Write Offs
AllowanceForDoubtfulAccountsReceivableWriteOffs
433000
CY2020Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
1012000
CY2020Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3134000
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3314000
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2404000
CY2020 us-gaap Lessee Finance Lease Lease Not Yet Commenced Description
LesseeFinanceLeaseLeaseNotYetCommencedDescription
The Company does not currently have any finance leases or executed leases that have not yet commenced.
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2018 us-gaap Operating Lease Expense
OperatingLeaseExpense
500000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P7Y1M6D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
760000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
465000
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
4164000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
616000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
641000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
637000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
646000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
660000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
1487000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
4687000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
972000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3715000
CY2020 us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
1075000
CY2019 us-gaap Sales Type Lease Selling Profit Loss
SalesTypeLeaseSellingProfitLoss
1179000
CY2020 us-gaap Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
1075000
CY2019 us-gaap Sales Type Lease Lease Income
SalesTypeLeaseLeaseIncome
1179000
CY2019 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
700000
CY2018 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
900000
CY2020Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Next Twelve Months
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedNextTwelveMonths
2074000
CY2020Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Two Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedTwoYears
1609000
CY2020Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received Three Years
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceivedThreeYears
535000
CY2020Q4 us-gaap Sales Type And Direct Financing Leases Lease Receivable Payments To Be Received
SalesTypeAndDirectFinancingLeasesLeaseReceivablePaymentsToBeReceived
4218000
CY2020Q4 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
4200000
CY2019Q4 us-gaap Sales Type Lease Lease Receivable
SalesTypeLeaseLeaseReceivable
2600000
CY2020Q4 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
0
CY2019Q4 us-gaap Sales Type Lease Unguaranteed Residual Asset
SalesTypeLeaseUnguaranteedResidualAsset
0
CY2020 us-gaap Operating Lease Lease Income
OperatingLeaseLeaseIncome
400000
CY2020Q4 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
150000
CY2020Q4 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
150000
CY2020 stim Amortization Period Of Deferred Sales Commissions
AmortizationPeriodOfDeferredSalesCommissions
P7Y
CY2020 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
900000
CY2019 us-gaap Amortization Of Deferred Sales Commissions
AmortizationOfDeferredSalesCommissions
400000
CY2020Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5023000
CY2019Q4 us-gaap Accrued Employee Benefits Current
AccruedEmployeeBenefitsCurrent
5724000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
292000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
373000
CY2020Q4 stim Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
138000
CY2019Q4 stim Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
674000
CY2020Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
536000
CY2019Q4 us-gaap Product Warranty Accrual Classified Current
ProductWarrantyAccrualClassifiedCurrent
639000
CY2020Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
726000
CY2019Q4 us-gaap Taxes Payable Current
TaxesPayableCurrent
700000
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
234000
CY2020Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
604000
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
687000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7319000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9031000
CY2020Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
35000000
CY2019Q4 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
30000000
CY2020Q4 stim Accrued Of Final Payment Fee
AccruedOfFinalPaymentFee
1925000
CY2019Q4 stim Accrued Of Final Payment Fee
AccruedOfFinalPaymentFee
1838000
CY2020Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
2305000
CY2019Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
690000
CY2020Q4 us-gaap Long Term Debt
LongTermDebt
34620000
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
31148000
CY2019Q4 us-gaap Long Term Debt Current
LongTermDebtCurrent
11250000
CY2020Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
34620000
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
19898000
CY2020 us-gaap Interest Expense Debt
InterestExpenseDebt
3900000
CY2020 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
600000
CY2019 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
3700000
CY2019 us-gaap Interest Expense Debt
InterestExpenseDebt
2900000
CY2019 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
800000
CY2018 us-gaap Interest Expense Borrowings
InterestExpenseBorrowings
3700000
CY2018 us-gaap Interest Expense Debt
InterestExpenseDebt
2900000
CY2018 us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
800000
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000.0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19100000
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19100000
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.044
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19114000
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
18645000
CY2020Q4 stim Common Stock Shares Issued And Reserved For Future Issuance
CommonStockSharesIssuedAndReservedForFutureIssuance
25582000
CY2019Q4 stim Common Stock Shares Issued And Reserved For Future Issuance
CommonStockSharesIssuedAndReservedForFutureIssuance
23046000
CY2020Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
105000
CY2018 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.035
CY2019 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4404000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3434000
CY2018 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1743000
CY2020Q1 us-gaap Revenues
Revenues
11476000
CY2020Q2 us-gaap Revenues
Revenues
9741000
CY2019 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2018 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2018 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.210
CY2020Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
864000
CY2019Q4 us-gaap Deferred Tax Assets Other
DeferredTaxAssetsOther
882000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
71559000
CY2020 stim Defined Contribution Plans Name
DefinedContributionPlansName
401(k) plan
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-27500000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-29000000.0
CY2018 us-gaap Net Income Loss
NetIncomeLoss
-24100000
CY2020 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
0
CY2020 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
0
CY2018 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.038
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
0.008
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.064
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense
EffectiveIncomeTaxRateReconciliationNondeductibleExpense
-0.007
CY2020 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.000
CY2019 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
-0.007
CY2018 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Research And Development
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment
0.006
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
-0.016
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.000
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Enacted Tax Rate
EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate
0.006
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.221
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.311
CY2018 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.267
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2018 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
61387000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
56157000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3008000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards Research
DeferredTaxAssetsTaxCreditCarryforwardsResearch
3008000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1431000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
1104000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
846000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
822000
CY2020Q4 stim Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
2361000
CY2019Q4 stim Deferred Tax Assets Interest Expense
DeferredTaxAssetsInterestExpense
1191000
CY2020Q4 stim Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
911000
CY2020Q4 stim Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
751000
CY2019Q4 stim Deferred Tax Assets Capitalized Start Up Costs
DeferredTaxAssetsCapitalizedStartUpCosts
1018000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
9000000.0
CY2020 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
6051000
CY2019 us-gaap Valuation Allowances And Reserves Charged To Cost And Expense
ValuationAllowancesAndReservesChargedToCostAndExpense
9031000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
64182000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
68856000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
62805000
CY2020Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
2703000
CY2019Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
1377000
CY2020Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Software
DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware
297000
CY2020Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
68856000
CY2019Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
62805000
CY2019Q4 us-gaap Deferred Tax Liabilities Deferred Expense Capitalized Software
DeferredTaxLiabilitiesDeferredExpenseCapitalizedSoftware
283000
CY2020Q4 stim Deferred Tax Liabilities Right Of Use Asset
DeferredTaxLiabilitiesRightOfUseAsset
838000
CY2020Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
1568000
CY2019Q4 us-gaap Deferred Tax Liabilities Prepaid Expenses
DeferredTaxLiabilitiesPrepaidExpenses
1094000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
2703000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
1377000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
6100000
CY2019Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
62805000
CY2018Q4 us-gaap Valuation Allowances And Reserves Balance
ValuationAllowancesAndReservesBalance
53774000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards Domestic
DeferredTaxAssetsOperatingLossCarryforwardsDomestic
247475000
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards State And Local
DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
152943000
CY2020Q4 stim Deferred Tax Assets Operating Loss Carryforwards Research And Development Credits
DeferredTaxAssetsOperatingLossCarryforwardsResearchAndDevelopmentCredits
3008000
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Expense
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
0
CY2019Q2 stim Reimbursement Revenue Per Treatment
ReimbursementRevenuePerTreatment
12000
CY2020 stim Distribution Agreements With Renewal Description
DistributionAgreementsWithRenewalDescription
The term of the distribution agreement will be automatically extended for two years unless either party gives the other party at least two years’ prior written of notice of non-renewal, except that the Company cannot decline to renew the agreement if Teijin has purchased 100% of its sales forecasts over the term of the agreement. 
CY2017 stim Distribution Agreement Renewal Period
DistributionAgreementRenewalPeriod
P2Y
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
19008000
CY2019Q3 us-gaap Revenues
Revenues
16000000
CY2019Q4 us-gaap Revenues
Revenues
17356000
CY2019Q1 us-gaap Cost Of Revenue
CostOfRevenue
2807000
CY2019Q2 us-gaap Cost Of Revenue
CostOfRevenue
4171000
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
4192000
CY2019Q4 us-gaap Cost Of Revenue
CostOfRevenue
4219000
CY2019Q1 us-gaap Gross Profit
GrossProfit
9921000
CY2019Q2 us-gaap Gross Profit
GrossProfit
12401000
CY2019Q3 us-gaap Gross Profit
GrossProfit
11808000
CY2019Q4 us-gaap Gross Profit
GrossProfit
13137000
CY2019Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
9592000
CY2019Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11523000
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10362000
CY2019Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
11516000
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4599000
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4261000
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4285000
CY2019Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4312000
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2786000
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3224000
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3489000
CY2019Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
4248000
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
16977000
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
18136000
CY2019Q4 us-gaap Operating Expenses
OperatingExpenses
20076000
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-7056000
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6607000
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-6328000
CY2019Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-6939000
CY2019Q1 us-gaap Interest Expense
InterestExpense
919000
CY2019Q2 us-gaap Interest Expense
InterestExpense
931000
CY2019Q3 us-gaap Interest Expense
InterestExpense
930000
CY2019Q4 us-gaap Interest Expense
InterestExpense
905000
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
446000
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
444000
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
391000
CY2019Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
290000
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-7529000
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-7094000
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-6867000
CY2019Q4 us-gaap Net Income Loss
NetIncomeLoss
-7554000
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.42
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.39
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.37
CY2019Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18026000
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18351000
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18508000
CY2019Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18627000
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
14277000
CY2020Q3 us-gaap Revenues
Revenues
12448000
CY2020Q4 us-gaap Revenues
Revenues
15579000
CY2020Q1 us-gaap Cost Of Revenue
CostOfRevenue
2811000
CY2020Q2 us-gaap Cost Of Revenue
CostOfRevenue
2323000
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
2657000
CY2020Q4 us-gaap Cost Of Revenue
CostOfRevenue
3763000
CY2020Q1 us-gaap Gross Profit
GrossProfit
8665000
CY2020Q2 us-gaap Gross Profit
GrossProfit
7418000
CY2020Q3 us-gaap Gross Profit
GrossProfit
9791000
CY2020Q4 us-gaap Gross Profit
GrossProfit
11816000
CY2020Q1 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
10723000
CY2020Q2 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
8151000
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
6053000
CY2020Q4 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
7635000
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5287000
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4010000
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4210000
CY2020Q4 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4729000
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
3021000
CY2020Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2116000
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1952000
CY2020Q4 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2112000
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
19031000
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
12215000
CY2020Q4 us-gaap Operating Expenses
OperatingExpenses
14476000
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-10366000
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-6859000
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2424000
CY2020Q4 us-gaap Operating Income Loss
OperatingIncomeLoss
-2660000
CY2020Q1 us-gaap Interest Expense
InterestExpense
1523000
CY2020Q2 us-gaap Interest Expense
InterestExpense
986000
CY2020Q3 us-gaap Interest Expense
InterestExpense
1002000
CY2020Q4 us-gaap Interest Expense
InterestExpense
1011000
CY2020Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-924000
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
200000
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
80000
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
8000
CY2020Q4 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
14000
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-12613000
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-7765000
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-3418000
CY2020Q4 us-gaap Net Income Loss
NetIncomeLoss
-3657000
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.68
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.41
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2020Q4 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18681000
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18747000
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18890000
CY2020Q4 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
19015000
CY2019Q1 us-gaap Revenues
Revenues
12728000
CY2019Q2 us-gaap Revenues
Revenues
16572000

Files In Submission

Name View Source Status
0001564590-21-010320-index-headers.html Edgar Link pending
0001564590-21-010320-index.html Edgar Link pending
0001564590-21-010320.txt Edgar Link pending
0001564590-21-010320-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R81.htm Edgar Link pending
R82.htm Edgar Link pending
R83.htm Edgar Link pending
R84.htm Edgar Link pending
R85.htm Edgar Link pending
R86.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
stim-10k_20201231.htm Edgar Link pending
stim-10k_20201231_htm.xml Edgar Link completed
stim-20201231.xsd Edgar Link pending
stim-20201231_cal.xml Edgar Link unprocessable
stim-20201231_def.xml Edgar Link unprocessable
stim-20201231_lab.xml Edgar Link unprocessable
stim-20201231_pre.xml Edgar Link unprocessable
stim-ex231_6.htm Edgar Link pending
stim-ex311_7.htm Edgar Link pending
stim-ex312_9.htm Edgar Link pending
stim-ex321_8.htm Edgar Link pending